This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

UMCC 2003-064 Resveratrol in Preventing Cancer in Healthy Participants (IRB 2004-535)

This study has been completed.
Information provided by:
National Cancer Institute (NCI) Identifier:
First received: December 8, 2004
Last updated: December 13, 2012
Last verified: March 2010
December 8, 2004
December 13, 2012
September 2004
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00098969 on Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
UMCC 2003-064 Resveratrol in Preventing Cancer in Healthy Participants
Phase I Single-Dose Safety and Phamacokinetics Clinical Study of Resveratrol AKA IRB 2003-424

RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming, growing, or coming back. The use of resveratrol may prevent cancer.

PURPOSE: This phase I trial is studying the side effects and best dose of resveratrol in preventing cancer in healthy participants.


  • Determine the concentration of resveratrol and its metabolites in the plasma, urine, and feces of healthy participants.
  • Correlate dose with systemic concentration of this drug and its metabolites in these participants.
  • Determine the safety of this drug in these participants.

OUTLINE: This is an open-label, dose-escalation, multicenter study.

Beginning 5 days before study drug administration, participants are put on a controlled diet (avoiding all resveratrol-containing food or drink) for washout. Participants receive oral resveratrol once on day 1.

Cohorts of 10 participants receive escalating doses of resveratrol until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 10 participants experience dose-limiting toxicity. A total of 16 participants are treated at the MTD.

Participants are followed at 2 and 7 days.

PROJECTED ACCRUAL: A total of 10-40 participants will be accrued for this study within 6 months.

Phase 1
Masking: None (Open Label)
Primary Purpose: Prevention
Unspecified Adult Solid Tumor, Protocol Specific
Drug: resveratrol
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Not Provided
Not Provided


  • Healthy participants



  • 18 to 80

Performance status

  • WHO 0-1

Life expectancy

  • Not specified


  • Absolute neutrophil count > 1,500/mm^3
  • Platelet count 120,000-450,000mm^3
  • Hemoglobin 10.5-17.5 g/dL for women OR 11.5-19.0 g/dL for men


  • Bilirubin 0.05-1.2 mg/dL
  • AST and ALT < 1.5 times normal


  • Creatinine normal
  • Urinalysis normal


  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile participants must use effective contraception
  • Willing to abstain from ingesting large quantities of resveratrol-containing foods
  • Willing to spend 24 hours in the hospital
  • No cancer diagnosis that is currently under treatment, is clinically detectable, or that has been treated within the past 5 years except basal cell or squamous cell skin cancer
  • No concurrent excessive alcohol intake (>21 units per week for men; 14 units per week for women)


Biologic therapy

  • Not specified


  • Not specified

Endocrine therapy

  • Concurrent hormone replace ment therapy allowed
  • Concurrent oral or depot contraceptives allowed


  • Not specified


  • Not specified


  • At least 2 weeks since prior and no concurrent vitamin supplements of any type
  • More than 6 months since prior and no concurrent participation in any other experimental study
  • No other concurrent chronic medications, including over-the-counter medications, herbal/natural preparations, or dietary supplements
  • No other concurrent prescribed medication
Sexes Eligible for Study: All
18 Years to 80 Years   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
United Kingdom,   United States
P30CA046592 ( U.S. NIH Grant/Contract )
Not Provided
Not Provided
Not Provided
Not Provided
National Cancer Institute (NCI)
Not Provided
Principal Investigator: Dean E. Brenner, MD University of Michigan Cancer Center
National Cancer Institute (NCI)
March 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP